Search research articles
Contact Us
Filters
Showing results (151-160 of 246) with videos related to
Page
of 25
Sort By:
Cancer
|
February 7, 2026
Control arm overperformance in phase 3 oncology clinical trials
Ansel P Nalin, Pavlos Msaouel, Adam J Grippin, et al.
JCO Oncology Practice
|
January 8, 2025
Incomplete Toxicity Reporting and Use of Toxicity-Minimizing Language in Phase III Oncology Trials
Avital M Miller, Adina H Passy, Alexander D Sherry, et al.
JAMA Network Open
|
March 28, 2024
Differential Treatment Effects of Subgroup Analyses in Phase 3 Oncology Trials From 2004 to 2020
Alexander D Sherry, Andrew W Hahn, Zachary R McCaw, et al.
The Journal of Urology
|
April 16, 2017
Outcomes of Patients with Renal Cell Carcinoma and Sarcomatoid Dedifferentiation Treated with Nephrectomy and Systemic Therapies: Comparison between the Cytokine and Targeted Therapy Eras
Sarp K Keskin, Pavlos Msaouel, Kenneth R Hess, et al.
Therapeutic Advances in Medical Oncology
|
June 19, 2026
Lineage infidelity in FH-deficient RCC with secondary somatic alterations: a case report and implications for diagnosis and treatment
Jianping Zhao, Derek B Allison, Giannicola Genovese, et al.
The Oncologist
|
April 1, 2021
Lenvatinib with or Without Everolimus in Patients with Metastatic Renal Cell Carcinoma After Immune Checkpoint Inhibitors and Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapies
Andrew J Wiele, Tharakeswara K Bathala, Andrew W Hahn, et al.
JCO Clinical Cancer Informatics
|
August 30, 2024
Increasing Power in Phase III Oncology Trials With Multivariable Regression: An Empirical Assessment of 535 Primary End Point Analyses
Alexander D Sherry, Adina H Passy, Zachary R McCaw, et al.
Clinical Genitourinary Cancer
|
October 9, 2021
Efficacy and safety of gemcitabine plus doxorubicin in patients with renal medullary carcinoma
Nathaniel R Wilson, Andrew J Wiele, Devaki Shilpa Surasi, et al.
JCO Precision Oncology
|
July 22, 2024
Molecular Characterization of Metastatic Oncocytoma With Exceptional Response to Treatment: A Case Report
Bradley R Webster, Christopher J Ricketts, Cathy D Vocke, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 8, 2025
Reproducibility of statistically significant phase III oncology trials: An In Silico meta-epidemiological analysis
Alexander D Sherry, Pavlos Msaouel, Avital M Miller, et al.
Page
of 25
Search research articles
Search
Showing results (151-160 of 246) with videos related to
Sort By:
Page
of 25
Cancer
|
February 7, 2026
Control arm overperformance in phase 3 oncology clinical trials
Ansel P Nalin, Pavlos Msaouel, Adam J Grippin, et al.
JCO Oncology Practice
|
January 8, 2025
Incomplete Toxicity Reporting and Use of Toxicity-Minimizing Language in Phase III Oncology Trials
Avital M Miller, Adina H Passy, Alexander D Sherry, et al.
JAMA Network Open
|
March 28, 2024
Differential Treatment Effects of Subgroup Analyses in Phase 3 Oncology Trials From 2004 to 2020
Alexander D Sherry, Andrew W Hahn, Zachary R McCaw, et al.
The Journal of Urology
|
April 16, 2017
Outcomes of Patients with Renal Cell Carcinoma and Sarcomatoid Dedifferentiation Treated with Nephrectomy and Systemic Therapies: Comparison between the Cytokine and Targeted Therapy Eras
Sarp K Keskin, Pavlos Msaouel, Kenneth R Hess, et al.
Therapeutic Advances in Medical Oncology
|
June 19, 2026
Lineage infidelity in FH-deficient RCC with secondary somatic alterations: a case report and implications for diagnosis and treatment
Jianping Zhao, Derek B Allison, Giannicola Genovese, et al.
The Oncologist
|
April 1, 2021
Lenvatinib with or Without Everolimus in Patients with Metastatic Renal Cell Carcinoma After Immune Checkpoint Inhibitors and Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapies
Andrew J Wiele, Tharakeswara K Bathala, Andrew W Hahn, et al.
JCO Clinical Cancer Informatics
|
August 30, 2024
Increasing Power in Phase III Oncology Trials With Multivariable Regression: An Empirical Assessment of 535 Primary End Point Analyses
Alexander D Sherry, Adina H Passy, Zachary R McCaw, et al.
Clinical Genitourinary Cancer
|
October 9, 2021
Efficacy and safety of gemcitabine plus doxorubicin in patients with renal medullary carcinoma
Nathaniel R Wilson, Andrew J Wiele, Devaki Shilpa Surasi, et al.
JCO Precision Oncology
|
July 22, 2024
Molecular Characterization of Metastatic Oncocytoma With Exceptional Response to Treatment: A Case Report
Bradley R Webster, Christopher J Ricketts, Cathy D Vocke, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 8, 2025
Reproducibility of statistically significant phase III oncology trials: An In Silico meta-epidemiological analysis
Alexander D Sherry, Pavlos Msaouel, Avital M Miller, et al.
Page
of 25